ProMIS Neurosciences
Toronto, CA · Canada (Federal Level) corporation · 1 known investors
Find your way into ProMIS Neurosciences
163 people in our graph share verified history with the ProMIS Neurosciences team — schools, employers, funds. One of them is your warm intro.
Cathy Friedmanunlockedknows EUGENE WILLIAMS · together at Harvard University (overlapped)
×10knows the team · via Harvard Business School
knows the team · via Harvard University
ProMIS Neurosciences is a clinical-stage biotechnology company developing antibody therapeutics that target toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's, ALS, and Parkinson's. The company operates in the biotechnology and neurology therapeutics space.
Founders & leadership
NC
Neil Cashman, M.D.Chief Scientific Officer and Co-founder
EW
EUGENE WILLIAMSinChairman and Co-FounderHe currently serves as CEO of Autoimmunity BioSolutions, and previously led Akashi Therapeutics as Chairman and CEO from 2010 to 2014. He also advised Red Sky Partners and sat on the board of the Muscular Dystrophy Association from 2018 to 2022.
RG
ROBERT GUNDELExecutive
JC
JANET CLENNETTinExecutive
NK
Neil K. WarmainPresident and Chief Executive Officer
EG
ELLIOT GOLDSTEINNamed on SEC filing
WW
WARREN WHITEHEADNamed on SEC filing
PK
PATRICK KIRWINNamed on SEC filing
NC
NEIL CASHMANNamed on SEC filing
WW
WILLIAM WYMANNamed on SEC filing
JM
JOHANNES MINHO ROTHNamed on SEC filing
Board
HB
HANS BLACKBoard director
Investors · 1
Funding
SEC filings, press & company announcements$38.3M disclosed across 21 of 22 rounds · 2012–2026
- Undisclosed amountPIPE financingJan 2026Source ↗
▶$7.5MraisedOct 2022 · 23 investors · BiotechnologyRule 506(b)
▶$7.5MraisedOct 2022 · 23 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Richard GregoryDirector
- Daniel GeffkenExecutive Officer
- Eugene WilliamsDirector
- Josh Mandel-BrehmDirector
- Larry AltstielExecutive Officer
- William WymanDirector
- Neil CashmanExecutive Officer, Director
- Gavin T. MalenfantExecutive Officer
- Gail M. FarfelExecutive Officer
- Neil K. WarmaDirector
- Patrick KirwinDirector
- Maggie ShafmasterDirector
- Offering amount
- $10.1M
- Amount sold
- $7.5M
- Minimum investment
- $27K
- Sales commissions
- $597.8K
- Placement agents
- CEROS FINANCIAL SERVICES, INC.
- First sale
- Oct 2022
- Incorporated
- Corporation, Canada (federal Level)
- Federal exemptions
- 06b
▶$18.1MraisedSep 2021 · 34 investors · BiotechnologyRule 506(b)
▶$18.1MraisedSep 2021 · 34 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- William WymanDirector
- Elliot GoldsteinExecutive Officer
- Daniel GeffkenExecutive Officer
- Patrick KirwinDirector
- Johanne KaplanExecutive Officer
- Richard GregoryDirector
- Neil CashmanExecutive Officer, Director
- Eugene WilliamsExecutive Officer, Director
- Offering amount
- $24.7M
- Amount sold
- $18.1M
- Sales commissions
- $12.7M
- Placement agents
- Ceros Financial Services, Inc.
- First sale
- Aug 2021
- Incorporated
- Corporation, Canada (federal Level)
- Federal exemptions
- 06b
▶$7MraisedMar 2021 · 7 investors · BiotechnologyRule 506(b)
▶$7MraisedMar 2021 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Elliot GoldsteinExecutive Officer, Director
- Eugene WilliamsExecutive Officer, Director
- William WymanDirector
- Patrick KirwinDirector
- Neil CashmanExecutive Officer, Director
- Richard GregoryDirector
- Steven PlotkinExecutive Officer
- Daniel E. GeffkenExecutive Officer
- Johanne KaplanExecutive Officer
- Offering amount
- $7M
- Amount sold
- $7M
- First sale
- Mar 2021
- Incorporated
- Corporation, Canada (federal Level)
- Federal exemptions
- 06b
▶$63KraisedNov 2020 · 3 investors · BiotechnologyRule 506(b)
▶$63KraisedNov 2020 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Elliot GoldsteinExecutive Officer, Director
- Eugene WilliamsExecutive Officer, Director
- William WymanDirector
- Johannes RothDirector
- Patrick KirwinDirector
- Neil CashmanExecutive Officer, Director
- Richard GregoryDirector
- Steven PlotkinExecutive Officer
- Daniel E. GeffkenExecutive Officer
- Johanne KaplanExecutive Officer
- James KupiecExecutive Officer
- Offering amount
- $147.2K
- Amount sold
- $63K
- First sale
- Nov 2020
- Incorporated
- Corporation, Canada (federal Level)
- Federal exemptions
- 06b
▶$100KraisedNov 2019 · 1 investors · BiotechnologyRule 506(b)
▶$100KraisedNov 2019 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Eugene WilliamsExecutive Officer, Director
- Elliot GoldsteinExecutive Officer, Director
- Anthony GiovinazzoDirector
- Richard GregoryDirector
- Neil CashmanExecutive Officer, Director
- James KupiecExecutive Officer
- Johannes RothDirector
- William WymanDirector
- Johanne KaplanExecutive Officer
- Daniel E. GeffkenExecutive Officer
- Patrick KirwinDirector
- Offering amount
- $273.3K
- Amount sold
- $100K
- First sale
- Nov 2019
- Incorporated
- Corporation, Canada (federal Level)
- Federal exemptions
- 06b
▶$119.4KraisedJan 2019 · 4 investors · BiotechnologyRule 506(b)
▶$119.4KraisedJan 2019 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Daniel E. GeffkenExecutive Officer
- Elliot GoldsteinExecutive Officer, Director
- Neil CashmanExecutive Officer, Director
- Patrick KirwinDirector
- Eugene WilliamsExecutive Officer, Director
- Richard GregoryDirector
- William WymanDirector
- Johanne KaplanExecutive Officer
- Johannes RothDirector
- Anthony GiovinazzoDirector
- Offering amount
- $367.9K
- Amount sold
- $119.4K
- First sale
- Jan 2019
- Incorporated
- Corporation, Canada (federal Level)
- Federal exemptions
- 06b
▶$1.7MraisedMay 2018 · 18 investors · BiotechnologyRule 506(b)
▶$1.7MraisedMay 2018 · 18 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Anthony GiovinazzoDirector
- Daniel E. GeffkenExecutive Officer
- Patrick KirwinDirector
- Johanne KaplanExecutive Officer
- Richard GregoryDirector
- Neil CashmanExecutive Officer, Director
- Johannes RothDirector
- Eugene WilliamsExecutive Officer, Director
- Elliot GoldsteinExecutive Officer, Director
- William WymanDirector
- Offering amount
- $2.8M
- Amount sold
- $1.7M
- Sales commissions
- $64.8K
- Placement agents
- Noble Capital Markets, Inc.
- First sale
- Apr 2018
- Incorporated
- Corporation, Canada (federal Level)
- Federal exemptions
- 06b
▶$704.1KraisedSep 2017 · 15 investors · BiotechnologyRule 506(b)
▶$704.1KraisedSep 2017 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Anthony GiovinazzoDirector
- Johannes RothDirector
- Johanne KaplanExecutive Officer
- Richard GregoryDirector
- Patrick D. KirwinDirector
- Neil CashmanExecutive Officer, Director
- Janet ClennettExecutive Officer
- Elliot GoldsteinExecutive Officer, Director
- William WymanDirector
- Eugene WilliamsExecutive Officer, Director
- Offering amount
- $1.1M
- Amount sold
- $704.1K
- Sales commissions
- $44.1K
- Placement agents
- Noble Capital Markets, Inc.
- First sale
- Aug 2017
- Incorporated
- Corporation, Canada (federal Level)
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 7
by search overlap
TradingView22 shared keywordsTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
Public22 shared keywordsPublic is a trading platform that allows users to buy and sell cryptocurrencies including Bitcoin, Ethereum, and memecoins through accounts managed by Zero Hash LLC, a New York State-licensed virtual currency business.
Seeking Alpha21 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Robinhood21 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
StockTwits21 shared keywordsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
Simply Wall St19 shared keywordsSimply Wall St is an investment platform that provides financial data visualization and analysis tools for individual investors. The platform serves long-term investors globally by simplifying complex market information into visual and narrative formats to make stock investing more accessible.
Perplexity18 shared keywordsAn AI-powered answer engine providing accurate, trusted, and real-time answers to questions.
Companies competing with ProMIS Neurosciences for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
ProMIS Neurosciences Sets September Investor Events | PMN Stock Newsstocktitan.net · Sep 2026Frequently asked questions
- What does ProMIS Neurosciences do?
- ProMIS Neurosciences is a clinical-stage biotechnology company developing antibody therapeutics that target toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's, ALS, and Parkinson's. The company operates in the biotechnology and neurology therapeutics space.
- Who founded ProMIS Neurosciences?
- ProMIS Neurosciences was founded by Neil Cashman, M.D..
- Who are ProMIS Neurosciences's investors?
- ProMIS Neurosciences's investors include Ally Bridge Group.
- How much funding has ProMIS Neurosciences raised?
- ProMIS Neurosciences has disclosed $38.3M raised across 21 of its 22 known rounds.
- Where is ProMIS Neurosciences headquartered?
- ProMIS Neurosciences is headquartered in Toronto, CA.